• 1
    Van Tubergen A, Landewe R, van der Linden S. Spondylarthropathies: options for combination therapy. Springer Semin Immunopathol 2001; 23: 14763.
  • 2
    Van Tubergen A, Landewe R, van der Heijde D, Hidding A, Wolter N, Asscher M, et al. Combined spa–exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum (Arthritis Care Res) 2001; 45: 4308.
  • 3
    Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994; 21: 22815.
  • 4
    Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants H, Dougados M. Outcome variables in ankylosing spondylitis: evaluation of their relevance and discriminant capacity. J Rheumatol 1999; 26: 9759.
  • 5
    Ruof J, Stucki G. Comparison of the Dougados Functional Index and the Bath Ankylosing Spondylitis Functional Index: a literature review. J Rheumatol 1999; 26: 95560.
  • 6
    Ruof J, Sangha O, Stucki G. Comparative responsiveness of 3 functional indices in ankylosing spondylitis. J Rheumatol 1999; 26: 195963.
  • 7
    Spoorenberg A, van der Heijde D, de Klerk E, Dougados M, de Vlam K, Mielants H, et al. A comparative study of the usefulness of the Bath Ankylosing Spondylitis Functional Index and the Dougados Functional Index in the assessment of ankylosing spondylitis. J Rheumatol 1999; 26: 9615.
  • 8
    Drummond M. Methods for the economic evaluation of health care programs. 2nd ed. Oxford: Oxford Medical Publications; 1997.
  • 9
    The Euro QoL Group. EuroQoL: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16: 199208.
  • 10
    Dolan P, Gudex C, Kind P, Williams A. The time trade-off method: results from a general population study. Health Econ 1996; 5: 14154.
  • 11
    Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095108.
  • 12
    Riteco JA, de Heij LJM, van Luijn JCF, Wolff I. Guidelines for pharmaco-economic research [in Dutch]. Amstelveen: College voor zorgverzekeringen; 1999.
  • 13
    Goossens ME, Rutten van Molken MP, Vlaeyen JW, van der Linden SM. The cost diary: a method to measure direct and indirect costs in cost-effectiveness research. J Clin Epidemiol 2000; 53: 68895.
  • 14
    Oostenbrink JB, Koopmanschap MA, Rutten FFH. Guidelines for cost-analysis: methods and guideline prices for economic evaluations in health care. [in Dutch] Amstelveen: College voor zorgverzekeringen; 2000.
  • 15
    Koopmanschap MA, van Ineveld BM. Towards a new approach for estimating indirect costs of disease. Soc Sci Med 1992; 34: 100510.
  • 16
    Koopmanschap MA, Rutten FFH. A practical guide for calculating indirect costs of disease. PharmacoEconomics 1996; 10: 4606.
  • 17
    Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ 1990; 300: 2305.
  • 18
    Pham B, Cranney A, Boers M, Verhoeven AC, Wells G, Tugwell P. Validity of area-under-the-curve analysis to summarize effect in rheumatoid arthritis clinical trials. J Rheumatol 1999; 26: 7126.
  • 19
    Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ 2000; 320: 1197200.
  • 20
    Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman & Hall; 1993.
  • 21
    Allard P, Deligne J, van Bockstael V, Duquesnoy B. Is spa therapy cost-effective in rheumatic disorders? Rev Rhum Engl Ed 1998; 65: 17380.
  • 22
    Graber-Duvernay B. Letter to the editor about the article: is spa therapy cost-effective in rheumatic disorders? Rev Rhum Engl Ed 1998; 65: 6002.
  • 23
    Mason J, Drummond M, Torrance G. Some guidelines on the use of cost effectiveness league tables. BMJ 1993; 306: 5702.
  • 24
    Drummond M, Torrance G, Mason J. Cost-effectiveness league tables: more harm than good? Soc Sci Med 1993; 37: 3340.
  • 25
    Bakker C, Hidding A, van der Linden S, van Doorslaer E. Cost effectiveness of group physical therapy compared to individualized therapy for ankylosing spondylitis: a randomized controlled trial. J Rheumatol 1994; 21: 2648.
  • 26
    Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis: results from the German rheumatological database: German Collaborative Arthritis Centers. J Rheumatol 2000; 27: 61322.
  • 27
    Boonen A, Chorus A, Miedema H, van der Heijde D, van der Tempel H, van der Linden S. Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patients. Ann Rheum Dis 2001; 60: 3538.
  • 28
    Brandt J, Haibel H, Cornely D, Golder W, Gonzalez J, Reddig J, et al. Successful treatment of active ankylosing spondylitis with the anti–tumor necrosis factor α monoclonal antibody infliximab. Arthritis Rheum 2000; 43: 134652.
  • 29
    Van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000; 59: 42833.
  • 30
    Van der Linden SM, Valkenburg HA, de Jongh BM, Cats A. The risk of developing ankylosing spondylitis in HLA–B27 positive individuals: a comparison of relatives of spondylitis patients with the general population. Arthritis Rheum 1984; 27: 2419.